A 5-year follow-up of those randomized to receive or not receive radioiodine after thyroidectomy showed nearly the same low ...

In honor of Thyroid Awareness Month, we are exploring the causes of thyroid diseases and thyroid cancer in our community.

Pembrolizumab is under clinical development by Merck and currently in Phase II for Follicular Thyroid Cancer. According to GlobalData, Phase II drugs for Follicular Thyroid Cancer have a 40% phase ...

Everything you need to know about thyroid cancer, from early warning signs to treatment options. Doctors reveal crucial ...

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.

Researchers conducted a randomized controlled trial to assess the need for postoperative radioiodine therapy among patients with low-risk thyroid cancer.

January is Thyroid Awareness Month. Learn how to spot the signs of thyroid issues and take proactive steps toward better ...